CincyTech Announces Election of New Board Member and Hiring of Life Sciences Analyst to Drive Innovation and Broader Impact

CincyTech announces the addition of Eric Baumgardner as a new board member and Logan Hille as Life Sciences Analyst. These additions further CincyTech's mission to invest in companies with novel, defensible intellectual property (IP) and accelerate the development of groundbreaking technologies that create new markets or disrupt current ones.

Eric Baumgardner joins the CincyTech board, contributing his expertise in corporate finance and strategic investments. As Vice President of Corporate Development for Western & Southern Financial Group, Baumgardner has led impactful mergers, acquisitions, and venture investments. Prior to joining Western & Southern Financial Group, Eric had a 25-year career at Procter & Gamble in senior financial roles, including corporate and global business development. He also serves as a visiting professor at Xavier University’s Williams College of Business, where he advises local companies on pricing strategy through the Center for Pricing Excellence.

Logan Hille joins CincyTech as a Life Sciences Analyst, bringing a strong scientific and technical background to support CincyTech's life sciences investment team. Logan holds a Ph.D. in Biological and Biomedical Sciences from Harvard University, where he conducted advanced research in gene-editing technology, working to enhance its transformative potential for diverse therapeutic applications.  During his tenure at Harvard University, Logan worked in the Office of Technology Development to support the commercialization of research.  Logan was also a member of the Harvard Biotech Club.  

Emma Off, CEO & President of CincyTech, commented, "We are thrilled to welcome Eric Baumgardner and Logan Hille to the CincyTech team. Logan's technical insight into life sciences technologies and experience helping translate novel IP at a major research institution and Eric's strategic financial acumen advance our mission to be the premier early-stage life sciences capital partner in the region. Their combined expertise strengthens our ability to identify, support, and scale innovations that have the potential to improve global health and patient outcomes."

With these additions, CincyTech reaffirms its commitment to finding and investing in groundbreaking therapies and technologies and supporting founders and research institutions in commercializing and bringing such therapies and technologies to market.